Financial Performance Overview
Gujarat Themis Biosyn Limited reported FY26 total income of ₹168.25 crores (9.80% growth YoY) with PAT of ₹46.68 crores. Revenue from operations stood at ₹1,658.3 crore (FY25: ₹1,508.0 crore) while net profit was ₹466.8 crore (FY25: ₹487.7 crore). Key financial metrics showed EBITDA growth of 9.71% to ₹75.53 crores, though net profit margin declined to 28.15% from 32.34% and return on equity decreased to 17.41% from 19.64%.
Strategic Developments & Operational Highlights
The company successfully completed fermentation block expansion at Vapi facility, increasing total fermentation capacity from 450 KL to 990 KL. A state-of-the-art multi-purpose synthetic and fermentation-based API facility was commissioned in May 2025. Total borrowings increased significantly to ₹159.9 crore from ₹29.9 crore YoY to finance these expansion projects.
Major Acquisitions
The company executed two significant post-balance sheet acquisitions: 1) Asset Purchase Agreement with Sanofi France in April 2026 for 13 global brands in anti-TB and anti-infective therapies (approx. ₹1,500 crore), providing access to over 55 countries; 2) Agreement to acquire 100% of MicroBiopharm Japan Co. Ltd. through subsidiary Themis Biosyn Japan Limited for approx. ₹1,300 crore, expanding therapy areas to immunosuppressants, oncology and anti-infectives.
Corporate Actions & Capital Structure
The board recommended a final dividend of ₹0.67 per equity share, totaling ₹7.30 crores. Share capital remained unchanged at ₹10.9 crore with 108,965,265 equity shares. The company incorporated three new subsidiaries: Themis Biosyn Japan Limited, Themis Biosyn Ireland Private Limited, and Themis Biosyn Private Limited.
Management & Board Changes
Dr. Sachin Patel was redesignated as Managing Director effective 1st July 2025. Mr. Nihar Parikh appointed as Independent Director, while Mr. Bhavik Shah resigned as CFO and was replaced by Mr. Krupesh Patel effective 1st April 2026.
Regulatory Compliance & Governance
The company filed its Integrated Annual Report including Business Responsibility and Sustainability Report as per SEBI LODR Regulation 34. No material orders were passed by regulators/courts during the year, no fraud was reported by auditors, and all applicable secretarial standards were complied with. The company maintained adequate internal financial controls with no material observations.
Future Outlook & Risk Management
The company focuses on organic and inorganic growth initiatives with API facility ramp-up and new product approvals expected to drive growth. Expansion into regulated markets (US, Europe) and R&D pipeline strengthening are key priorities. Gearing ratio increased to 19.17% from 2.61% YoY due to increased borrowings, representing a key financial risk factor.